The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Metastatic Breast Cancer
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Phase 1/1b/2 Study of Oral PMD-026 in Patients with Metastatic Breast Cancer
-
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234
University of California, Los Angeles (UCLA), Los Angeles, California, United States, 90095
Moffitt Cancer Center, Tampa, Florida, United States, 33612
Ohio State University, Columbus, Ohio, United States, 43210
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Phoenix Molecular Designs,
2026-03